PharmaMar, S.A.

Industry

  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals

Other Names/Subsidiaries

  • Grupo Zeltia
  • PharmaMar
  • Zeltia Group
See more in Biomedtracker

Latest on PharmaMar, S.A.

Pink Sheet

PharmaMar Seeks EU Fast-Track Status For ‘Practice-Changing’ ES-SCLC Therapy

 
• By Neena Brizmohun

PharmaMar and Boehringer Ingelheim are the latest companies to ask the European Medicines Agency to fast track its review of their planned EU marketing authorization applications (MAAs) for their resp

Pink Sheet

PharmaMar’s Aplidin Back On EMA’s Agenda After Conflict Of Interest Controversy

 
• By Neena Brizmohun

There is expected to be activity at the European Medicines Agency this week regarding the re-evaluation of PharmaMar’s EU marketing application for Aplidin (plitidepsin), which was rejected in 2018 in

Scrip

Singapore ADC Specialist Axcynsis Nets Novel Payload To Address Drug Resistance

 
• By Dexter Jie Yan

In a shot at repeating Daiichi Sankyo Co., Ltd. ’s hugely successful development of deruxtecan as a cytotoxic payload, the holy grail in the design of antibody-drug conjugates (ADCs), Singapore-based

Scrip

Merck & Co. and Daiichi’s Phase II ADC Hit Raises Expectations

 
• By Elizabeth Cairns

The Phase III trial of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd. ’s ifinatamab deruxtecan (I-DXd) in small-cell lung cancer (SCLC) will report in 2027, and following the recent misfire with an